Studying immunologic activity and reactogeneity of "EnceVirr" vaccine during immunization using express-scheme
Автор: Shoutova N.A., Shkouratova O.V., Rouzavina Ye.V., Vlasova N.M., Stavitskaya N.Kh., Vorobyova M.S., Ladyzhenskaya I.P., Solyanik R.G.
Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk
Рубрика: Клинические исследования
Статья в выпуске: 2-2 т.24, 2009 года.
Бесплатный доступ
Comparative assessment of express-scheme (0.14) vaccination against forest-spring encephalitis using vaccines "EnceVirR" (FGUP SMS Microgen, branch NPO Virion Tomsk, Russia) and FSMEImmun RInject (Baxter, Austria) aimed at assessing their immunologic activity and reactogeneity was performed on volunteers of both sexes aged 18- 70 years. Serocoversion for EnceVirR vaccine was 98% (on the 14-th and 30-th days after vaccination) and those for FSME-Immun vaccine were 86% (on the 14-th day) and 96% (on the 30-th day after vaccination).
Forest-spring encephalitis, vaccine, express-scheme of vaccination, serologic reactions, safety, reactogeneity, immunogeneity
Короткий адрес: https://sciup.org/14919057
IDR: 14919057
